| Not Sold on AVI BioPharma... Yet VFC submits: Avi BioPharma, Inc. (AVII) is back on the radar of late, after releasing some positive news reports. On Monday morning Avi announced that it had landed a government contract with the U.S. Defense Threat Reduction Agency [DTRA] for the development of AVI-7100 (formerly identified as AVI-7367) as a medical countermeasure to a possible H1N1 virus pandemic outbreak. The contract could be worth up to $18 million. Just two months earlier, AVI had announced a similar agreement with the DTRA, with that contract being worth up to $4 million.Last week Avi also announced the positive results of a Phase 1b-2 clinical study for the company's drug treatment for Duchenne muscular dystrophy [DMD]. The study included 28 patients and was well tolerated by all, according to reports issued by the company.Complete Story » seekingalpha.com |
How to Get Your Groove Back Everything from falling hormones and child rearing to rising responsibilities and job loss can dampen libido. online.wsj.com |
St. Jude Medical In Settlement Talks St. Jude Medical is in settlement talks with the Justice Department regarding allegations the heart-device maker used medical studies to pay kickbacks and boost product usage. online.wsj.com |
RepHresh Brilliant pH tampons - Video Introducing RepHresh Brilliant pH Tampons feedproxy.google.com |
Pfizer Loses in Court ... Again Pharmalot submits: The Nevada Supreme Court has upheld a $58 million judgment that was awarded to three Nevada women, who claimed they suffered breast cancer after taking the Prempro hormone replacement therapy made by Wyeth, which is now owned by Pfizer (PFE). The ruling confirms a 2007 decision in favor of Arlene Rowatt, Jeraldine Scofield and Pamela Forrester, who were originally awarded $134 million, but that was later reduced by the trial judge (back story here and here). Forrester and Rowatt, however, have reportedly since passed away.In explaining the 6-0 decision, Justice Michael Cherry wrote noted that studies dating back to the 1980s found links between breast cancer and the drug. Yet, he wrote, “internal Wyeth documents show that it responded to studies suggesting a possible breast cancer risk by downplaying the risk through public relations campaigns and its sales representatives’ interactions with physicians” (read the ruling here).Complete Story » seekingalpha.com |